I want to thank everyone for the excellent discussion so far. Today, I wanted to ask a specific question about Figure 1B and D. In these charts, the anti-factor Xa activity was evaluated over time in the rivaroxaban study. In each of these charts, there seems to be a rebound increase in anti-factor Xa activity relative to placebo after the curves cross each other. This phenomenon is also seen in Figure 3B and D, which plot the amount of unbound rivaroxaban over time. Of note, this is not seen in the apixaban group, and does not carry over to the thrombin curves. Why would we see this effect, and particularly, why in rivaroxaban? Do you think this finding may be clinically important?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.